A Phase 1 interventional study of BI 1015550 and Moxifloxacin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this trial is to evaluate the effects of a single therapeutic and a single supra-therapeutic dose of BI 1015550 following oral administration on cardiac safety parameters in healthy male and female volunteers.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Either male subjects, or female subjects meet the following criteria requiring highly effective from at least 30 days before the first administration of trial medication until 37 days after the last administration of the study drug:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments ordered as described below. Each treatment was administered orally with 240 mL of water after an overnight fast of at least 10 hours. Each treatment was separated by a wash-out period of at least 7 days. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments ordered as described below. Each treatment was administered orally with 240 mL of water after an overnight fast of at least 10 hours. Each treatment was separated by a wash-out period of at least 7 days. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments ordered as described below. Each treatment was administered orally with 240 mL of water after an overnight fast of at least 10 hours. Each treatment was separated by a wash-out period of at least 7 days. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
Participants in this study received five treatments ordered as described below. Each treatment was administered orally with 240 mL of water after an overnight fast of at least 10 hours. Each treatment was separated by a wash-out period of at least 7 days. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control.
Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo
BI 1015550 administered as low (L), and high (H), dose. Oral tablet.
Also known as: Nerandomilast, JASCAYD®
Moxifloxacin was used as positive control, given as a high dose. Oral tablet.
Also known as: Avelox®
Placebo was administered as low (P1), matching the low-dose nerandomilast group, and as high (P2), matching the high-dose neradnomilast group. Oral tablet.
The Maximum Mean Difference Between Each Single Dose of Either a Low Dose or a High Dose of Nerandomilast and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration
QT interval corrected for heart rate (using the method of Fridericia, QTcF) changes from baseline, measured between 20 minutes and 24 hours after drug administration, were analyzed using a linear Mixed Model for Repeated Measures (MMRM). Pairwise comparison was used to compare the QTcF changes for each dose of nerandomilast (e.g., low dose, high dose) with the placebo at every time point. Mean treatment differences in the QTcF changes from baseline at each time point were estimated by the differences in the corresponding least-squares means. Two-sided 90% confidence intervals based on the t-distribution were computed for each time point. The MMRM was adjusted for the discrete fixed effects treatment, period, time, the continuous fixed effects period- and participant-baseline, the fixed effect-by-time terms, participant as random effect and time within period as a repeated effect per participant. The covariance structure for the repeated effect time was unstructured.
Time frame: MMRM included measurements at these time points [hours:minutes] post-drug: 0:20, 1:00, 1:30, 2:00, 2:30, 3:00, 3:30, 4:00, 4:30, 5:00, 6:00, 8:00, 12:00, and 24:00. MMRM values at 12:00 (low dose) and 4:30 (high dose) are shown in the table below.
The Maximum Mean Difference Between Moxifloxacin and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration.
QT interval corrected for heart rate (using the method of Fridericia, QTcF) changes from baseline, measured between 20 minutes and 24 hours after drug administration, were analyzed using a linear Mixed Model for Repeated Measures (MMRM). Pairwise comparison was used to compare the QTcF changes for moxifloxacin with the placebo at every time point. Mean treatment differences in the QTcF changes from baseline at each time point were estimated by the differences in the corresponding least-squares means. Two-sided 90% confidence intervals based on the t-distribution were computed for each time point. The MMRM was adjusted for the discrete fixed effects treatment, period, time, the continuous fixed effects period- and participant-baseline, the fixed effect-by-time terms, participant as random effect and time within period as a repeated effect per participant. The covariance structure for the repeated effect time was unstructured.
Time frame: MMRM included measurements at these time points [hours:minutes] post-drug: 0:20, 1:00, 1:30, 2:00, 2:30, 3:00, 3:30, 4:00, 4:30, 5:00, 6:00, 8:00, 12:00, and 24:00. MMRM values at 3:30 (high dose moxifloxacin) are shown in the table below.
This randomized, placebo-controlled, double-blind (moxifloxacin: open-label), crossover study had 5 treatment periods separated by ≥7-day washouts. Treatments included a low dose nerandomilast \[L\], a high dose nerandomilast \[H\], a high dose moxifloxacin (positive control) \[M\]), and placebo \[P1, P2\]. The study assessed nerandomilast's effect on cardiac safety (QT/QTc interval) in healthy female and male participants across 15 sequences, each with 3 participants.
| Milestone | Sequence 1: H/M/P2/L/P1 | Sequence 2: H/P1/L/P2/M | Sequence 3: H/L/P2/M/P1 | Sequence 4: M/H/L/P1/P2 | Sequence 5: M/P1/L/H/P2 | Sequence 6: M/P2/H/L/P1 | Sequence 7: P1/M/H/P2/L | Sequence 8: P1/P2/H/M/L | Sequence 9: P1/L/M/H/P2 | Sequence 10: P2/H/P1/M/L | Sequence 11: P2/P1/M/L/H | Sequence 12: P2/L/M/P1/H | Sequence 13: L/H/P1/P2/M | Sequence 14: L/M/P2/P1/H | Sequence 15: L/P2/P1/H/M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: H/M/P2/L/P1 | Sequence 2: H/P1/L/P2/M | Sequence 3: H/L/P2/M/P1 | Sequence 4: M/H/L/P1/P2 | Sequence 5: M/P1/L/H/P2 | Sequence 6: M/P2/H/L/P1 | Sequence 7: P1/M/H/P2/L | Sequence 8: P1/P2/H/M/L | Sequence 9: P1/L/M/H/P2 | Sequence 10: P2/H/P1/M/L | Sequence 11: P2/P1/M/L/H | Sequence 12: P2/L/M/P1/H | Sequence 13: L/H/P1/P2/M | Sequence 14: L/M/P2/P1/H | Sequence 15: L/P2/P1/H/M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: H/M/P2/L/P1 | Sequence 2: H/P1/L/P2/M | Sequence 3: H/L/P2/M/P1 | Sequence 4: M/H/L/P1/P2 | Sequence 5: M/P1/L/H/P2 | Sequence 6: M/P2/H/L/P1 | Sequence 7: P1/M/H/P2/L | Sequence 8: P1/P2/H/M/L | Sequence 9: P1/L/M/H/P2 | Sequence 10: P2/H/P1/M/L | Sequence 11: P2/P1/M/L/H | Sequence 12: P2/L/M/P1/H | Sequence 13: L/H/P1/P2/M | Sequence 14: L/M/P2/P1/H | Sequence 15: L/P2/P1/H/M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: H/M/P2/L/P1 | Sequence 2: H/P1/L/P2/M | Sequence 3: H/L/P2/M/P1 | Sequence 4: M/H/L/P1/P2 | Sequence 5: M/P1/L/H/P2 | Sequence 6: M/P2/H/L/P1 | Sequence 7: P1/M/H/P2/L | Sequence 8: P1/P2/H/M/L | Sequence 9: P1/L/M/H/P2 | Sequence 10: P2/H/P1/M/L | Sequence 11: P2/P1/M/L/H | Sequence 12: P2/L/M/P1/H | Sequence 13: L/H/P1/P2/M | Sequence 14: L/M/P2/P1/H | Sequence 15: L/P2/P1/H/M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: H/M/P2/L/P1 | Sequence 2: H/P1/L/P2/M | Sequence 3: H/L/P2/M/P1 | Sequence 4: M/H/L/P1/P2 | Sequence 5: M/P1/L/H/P2 | Sequence 6: M/P2/H/L/P1 | Sequence 7: P1/M/H/P2/L | Sequence 8: P1/P2/H/M/L | Sequence 9: P1/L/M/H/P2 | Sequence 10: P2/H/P1/M/L | Sequence 11: P2/P1/M/L/H | Sequence 12: P2/L/M/P1/H | Sequence 13: L/H/P1/P2/M | Sequence 14: L/M/P2/P1/H | Sequence 15: L/P2/P1/H/M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QT interval corrected for heart rate (using the method of Fridericia, QTcF) changes from baseline, measured between 20 minutes and 24 hours after drug administration, were analyzed using a linear Mixed Model for Repeated Measures (MMRM). Pairwise comparison was used to compare the QTcF changes for each dose of nerandomilast (e.g., low dose, high dose) with the placebo at every time point. Mean treatment differences in the QTcF changes from baseline at each time point were estimated by the differences in the corresponding least-squares means. Two-sided 90% confidence intervals based on the t-distribution were computed for each time point. The MMRM was adjusted for the discrete fixed effects treatment, period, time, the continuous fixed effects period- and participant-baseline, the fixed effect-by-time terms, participant as random effect and time within period as a repeated effect per participant. The covariance structure for the repeated effect time was unstructured.
| Milliseconds | Low-dose nerandomilast | High-dose nerandomilast |
|---|---|---|
| The Maximum Mean Difference Between Each Single Dose of Either a Low Dose or a High Dose of Nerandomilast and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration | 3.0 (0.7 to 5.4) | 3.2 (1.2 to 5.2) |
QT interval corrected for heart rate (using the method of Fridericia, QTcF) changes from baseline, measured between 20 minutes and 24 hours after drug administration, were analyzed using a linear Mixed Model for Repeated Measures (MMRM). Pairwise comparison was used to compare the QTcF changes for moxifloxacin with the placebo at every time point. Mean treatment differences in the QTcF changes from baseline at each time point were estimated by the differences in the corresponding least-squares means. Two-sided 90% confidence intervals based on the t-distribution were computed for each time point. The MMRM was adjusted for the discrete fixed effects treatment, period, time, the continuous fixed effects period- and participant-baseline, the fixed effect-by-time terms, participant as random effect and time within period as a repeated effect per participant. The covariance structure for the repeated effect time was unstructured.
| Milliseconds | High-dose moxifloxacin - Positive Control |
|---|---|
| The Maximum Mean Difference Between Moxifloxacin and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration. | 14.2 (12.4 to 16.1) |
Collected over Adverse Events: up to 7 days following drug administration for placebo 1 and 2, low-dose nerandomilast, and high-dose nerandomilast, and for up to 4 days following administration of high-dose moxifloxacin. All-Cause Mortality: from the first drug administration on Day 1 until the end of the trial, up to a total of 44 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo 1 | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) |
| Placebo 2 | 0/46 (0%) | 0/46 (0%) | 4/46 (8.7%) |
| Low-dose nerandomilast | 0/45 (0%) | 0/45 (0%) | 4/45 (8.9%) |
| High-dose nerandomilast | 0/45 (0%) | 0/45 (0%) | 3/45 (6.7%) |
| High-dose moxifloxacin - Positive Control | 0/45 (0%) | 0/45 (0%) | 3/45 (6.7%) |
| Event | Placebo 1 | Placebo 2 | Low-dose nerandomilast | High-dose nerandomilast | High-dose moxifloxacin - Positive Control |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/45 | 4/46 | 4/45 | 3/45 | 3/45 |
Treated set (TS): The treated set includes all subjects who were treated with at least one dose of trial drug.
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 36.9 ± 8.8 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 21 |
| Male | 25 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 43 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 44 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Mar 2024 to primary completion in Jul 2024, 4 months.
Results were first posted in Nov 2025, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerandomilast